Masayuki Inoo

Comparison of adding tocilizumab to methotrexate with switching to tocilizumab in patients with rheumatoid arthritis with inadequate response to methotrexate: 52-week results from a prospective, randomised, controlled study (SURPRISE study)

Yuko Kaneko, Tatsuya Atsumi, Yoshiya Tanaka et al. · Annals of the Rheumatic Diseases · 2016 · 113 citations · Full text

Medicine, Clinical Sciences, Pharmacotherapy +15

Association of Higher Methotrexate Dose With Lymphoproliferative Disease Onset in Rheumatoid Arthritis Patients

Tomohiro Kameda, Hiroaki Dobashi, Nobuyuki Miyatake et al. · Arthritis Care & Research · 2014 · 93 citations

Medicine, Internal Medicine, Pharmacotherapy +13

Tocilizumab discontinuation after attaining remission in patients with rheumatoid arthritis who were treated with tocilizumab alone or in combination with methotrexate: results from a prospective randomised controlled study (the second year of the SURPRISE study)

Yuko Kaneko, Masaru Kato, Yoshiya Tanaka et al. · Annals of the Rheumatic Diseases · 2018 · 50 citations · Full text

Medicine, Immunology, Pharmacotherapy +15

Longterm Safety and Efficacy of Subcutaneous Tocilizumab Monotherapy: Results from the 2-year Open-label Extension of the MUSASHI Study

Atsushi Ogata, Koichi Amano, Hiroaki Dobashi et al. · The Journal of Rheumatology · 2015 · 47 citations · Full text

Medicine, Internal Medicine, Pharmacotherapy +15

Sustained discontinuation of infliximab with a raising-dose strategy after obtaining remission in patients with rheumatoid arthritis: the RRRR study, a randomised controlled trial

Yoshiya Tanaka, Koji Oba, Takao Koike et al. · Annals of the Rheumatic Diseases · 2019 · 22 citations · Full text

Medicine, Clinical Sciences, Pharmacotherapy +15